Benjakul supplementation improves hepatic fat metabolism in high-fat diet-induced obese rats

Achiraya Kamchansuppasin1*, Kevalin Vongthoung2, Pornthep Temrangsee1, Narongsuk Munkong3, Nusiri Lerdvuthisopon4

1Office of Graduate Studies, Faculty of Medicine, Thammasat University, Pathum Thani, 2Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 3Office Department of Medicine, School of Medicine, University of Phayao, Phayao, 4Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand

*For correspondence: Email: achiraya.chi@yahoo.com; Tel: +66 9 7267 1932

Sent for review: 4 August 2018 Revised accepted: 25 January 2020

Abstract

Purpose: To evaluate the effects of Benjakul water extract (BWE) supplementation for the prevention of hepatic fat metabolic dysfunction in a rat obesity model induced by a high-fat diet (HFD).

Methods: Forty male outbred Sprague-Dawley rats were separated into six groups according to diet composition and treatment: control, HFD, and HFD supplemented with Benjakul extraction at low and high dose (41.3 and 413 mg/kg/day, respectively). After 4 weeks, blood biochemical parameters (i.e., hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) enzyme and liver histological features) were examined. Subsequently, hepatic gene expression of sterol regulatory element binding protein-1 (SREBP-1) and nuclear factor-kappa B (NF-kB) were investigated.

Results: Low and high doses of BWE showed significant prevention of abdominal fat accumulation (p < 0.05) and inhibited hypercholesterolemia without restoring triglyceride (TG) and lipoprotein-cholesterol (LDL-C) in serum compared to rats fed HFD alone. BWE hindered hepatic fat accumulation via suppression of SREBP-1 expression and HMGCR activity in HFD-induced obese rats, while significantly promoting NF-kB down regulation (p < 0.05).

Conclusion: BWE may be a novel prophylactic strategy for preventing metabolic syndrome and to protect against steatosis due to its regulatory effects on lipid homeostasis.

Keywords: Benjakul, Fat metabolism, Non-alcoholic fatty liver disease, High-fat diet

INTRODUCTION

Being overweight or obese is strongly associated with and can cause metabolic syndrome. The risk factors due to obesity, especially visceral fat deposition and hypercholesterolemia, have a robust impact on the development of metabolic syndrome leading to pivotal causes of mortality [1]. Being overweight is associated with high levels of plasma lipids and lead to metabolic disorders, such as increased plasma low-density lipoprotein-cholesterol (LDL-C) and triglyceride (TG) concentrations [2]. An imbalance in fatty acid metabolism results in the accumulation of TG in hepatocytes. Thus, non-alcoholic fatty liver disease (NAFLD) is the most common cause of
liver disease. In general, dietary fat intake is a culprit of adiposity [3]. Increase in high fat mass potentiates associated risk conditions, such as dyslipidemia, type II diabetes mellitus, and coronary heart disease [4].

Moreover, high-fat diets (HFDs) contribute to glucose tolerance impairment and insensitivity of insulin toward blood glucose [5]. This impact is seen not only in humans but also in animals. Animals fed with a HFD for 4 weeks have a high propensity for obesity and abnormal lipid biomarkers [6].

In the concept of Ayurveda, dhatus (tissues) are the basic structures of the body [7]. The purpose of metabolism is to gather every dhatu together in harmony to achieve their individual roles within the body. According to animism, “Benjakul” is a mixture of elements that regulate body homeostasis [8]. In Thai traditional medicine pharmacopeia, Benjakul is associated with an ancient philosophical concept used to normalize the five primary elements.

The herbal components function as antioxidants, demonstrating broad pharmacological and biological benefits. The herbal elements not only have anti-cancer and cytotoxic activities, but some have an anti-diabetes effect. The major phytochemical constituent of Benjakul extract is piperine [9]. Significantly, piperine can reduce not only serum TG, total cholesterol (TC), and LDL-C levels, but also high-density lipoprotein (HDL) levels, affirming its beneficial effect on reducing dyslipidemia [10]. Unfortunately, most studies of Benjakul have focused only on toxicity.

In this study, we studied the effects of Benjakul supplementation on molecular modulation of rat liver abnormalities.

**EXPERIMENTAL**

**Preparation of Benjakul water extract (BWE)**

Benjakul is composed of five dried medicinal plants (Table 1). Five individual plants were collected from the Rayong Province, Thailand. The decoction method was based on the Thai Traditional Pharmacopeia guidelines.

All plants were cleaned and placed in a hot air oven at 55°C until dry. Dried plants were homogenized using a grinder. The powdered herbs were boiled at 100°C in water until half of the volume remained. The filtrate was evaporated via lyophilization.

<table>
<thead>
<tr>
<th>Common name</th>
<th>Scientific name</th>
<th>Part used</th>
<th>Content (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild betal leaf bush</td>
<td><em>Piper sarmentosum</em> Roxb.</td>
<td>Root</td>
<td>44.4</td>
</tr>
<tr>
<td>Pepper wood</td>
<td><em>Piper interruptum</em> Opiz.</td>
<td>Stem</td>
<td>22.2</td>
</tr>
<tr>
<td>Rose-color lead wood</td>
<td><em>Plumbago indica</em> Linn.</td>
<td>Root</td>
<td>16.7</td>
</tr>
<tr>
<td>Long pepper</td>
<td><em>Piper retrofractum</em> Vahl.</td>
<td>Fruit</td>
<td>11.1</td>
</tr>
<tr>
<td>Ginger</td>
<td><em>Zingiber mekongense</em> Gagnep.</td>
<td>Rhizome</td>
<td>5.6</td>
</tr>
</tbody>
</table>

**Study design**

Forty 3-week-old male outbred Sprague-Dawley rats were obtained from the National Laboratory Animal Center, Nakhon Pathom, Thailand. All rats were maintained individually in stainless steel cages under standard conditions: 12-h light-dark cycle at 24°C. Rats were fed a commercial standard chow diet for one week to acclimate. According to diet composition and treatments, rats were randomly divided into four groups: (1) standard chow (C), (2) HFD (HF), (3) HFD supplemented with low-dose BWE (HFB1, 41.3 mg/kg body weight/day), and (4) HFD supplemented with high dose BWE (HFB10, 413 mg/kg body weight/day). The energy of standard chow was 3.04 kcal/g, whereas the HFD was 5.12 kcal/g (60 % fat). The obesity-inducing diet was modified from a study by Claret [11]. The HFD was composed of egg yolk (21.3%), margarine (21.3 %), wheat flour (15.9%), pork belly (10.6 %), pork liver (10.6 %), standard chow (10.6 %), sugar (6.2 %), and egg white (3.5 %).

Body weights and food intake were recorded daily during the experimental period. After 4 weeks, blood and tissue organs were collected for biochemical, pathological, and gene expression analyses. This protocol was permitted by the Animal Ethics Committee, Faculty of Medicine, Thammasat University (approval no. AE 001/2015) [12].

**Clinical biochemical analysis**

The TG, TC, and HDL-C concentrations in serum were measured using commercial enzymatic kits (Fluitest test kits, Analyticon Biotechnologies AG, Germany) using an enzymatic colorimetric method. LDL-C levels were calculated following the Friedewald equation [13].
Measurement of hepatic TC and TG accumulation

Hepatic TC and TG content were extracted from 50 mg fresh liver using isopropanol following a previously established protocol [14]. Extracts were centrifuged at 10,000×g for 15 min at 4°C. TC and TG concentrations were measured using FluiTest lipid assay kits and expressed as mg/g tissue.

Determination of HMGCR activity

Microsomal fraction was derived from one gram of liver tissue by homogenized and centrifuged at 100,000×g for 60 min at 4°C. HMGCR activities were measured using a commercial kit from Sigma-Aldrich, Saint Louis, MO, USA and expressed as mmol/min/mg protein (Units/mg protein).

Histological examination

For histologic examination, right ventral lobes of liver tissues and epididymal fat pads were fixed in 10% neutral-buffered formaldehyde, embedded in paraffin, cut using a rotary microtome, floated onto warm (40-45°C) water to remove wrinkles, mounted on slides, and stained according to a standard hematoxylin and eosin (H&E) protocol. Samples were examined for morphological observations under a light microscope (Olympus, Japan). The areas of adipocytes were measured using AxioVision AC (Carl Zeiss, Germany). Mean adipocyte areas were calculated from 100 cells observed/um².

Quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis

Total liver RNA was extracted by the TRizol isolation method using the manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). For quantitative RT-PCR, first-strand cDNA was synthesized from 200 ng of total RNA using high-capacity cDNA reverse transcription kits (Bio-Rad, Hercules, CA, USA) [15]. Samples were subjected to quantitative amplification using TaqMan probes and primer sets for rat SREBP-1c (Rn1495769m1) and NF-κB p65 (Rn1502266m1). Relative mRNA levels were analyzed using the 2-ΔΔCT method. The expression of target genes was normalized to GAPDH (Rn99999916_s1) expression as a housekeeping gene.

Western blot analysis

Total proteins from liver tissues were isolated using cell lysis buffer (Cell Signaling Technology, CAT#9803, Danvers, MA, USA) following the manufacturer’s instructions. Total protein concentrations were determined using Bradford protein assay kits (Bio-Rad, CAT#5000201, Hercules, CA, USA). Extracted protein (50 µg) was subjected to 7% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes (Bio-Rad). Membranes were blocked by a mixture of Odyssey blocking buffer (LI-COR Bioscience, Lincoln, NE, USA) for 1 h in the dark at room temperature and then, an overnight incubation in a primary anti-SREBP-1 antibody, anti-NF-κB p65 antibody, or anti-GAPDH antibody (Cell Signaling Technology, Danvers, MA, USA) at 4°C. Membranes were washed with Tris-buffered saline containing 0.1% Tween-20. They were incubated with DyLight 680-conjugated antibodies (Cell Signaling Technology, Danvers, MA, USA) in the dark at room temperature for 1 h. The densities of each band were determined using an Odyssey Fc imaging system (LI-COR Bioscience, Lincoln, NE, USA) after washing. GAPDH protein levels were used for normalization.

Statistical analysis

All data are expressed as the mean ± SEM, n = 8 calculated using the IBM Statistics Package SPSS for Windows version 20. One-way ANOVA tests were used for statistical analysis of variance. Comparisons of the different groups were performed using least significant difference post-hoc tests. P values < .05 were considered statistically significant for all data.

RESULTS

Effect of BWE on body weight, organ weight, and histology of epididymal fat

The C group had a lower caloric intake compared to the HFD groups, even though the C group consumed the highest amount of food. After 4 weeks of experimental diets, all HFD groups (HF, HFB1 and HFB10) showed increases in body weights by 24 – 39 % compared with the control group (Table 2). The HFD groups showed a significant (p <0.05) increase in both final body weight and internal organ weights. Importantly, the internal organ weights (epididymal and omental fat) of HFB10 rats were lower than that of the HF group (Figures 1 A, B and D). Histological H&E staining confirmed increased epididymal adipocyte size in the HF group compared to the HFBL10 group (Figure 2). Quantitative assessment of adipocyte size indicated that the HF group had 2-fold larger...
epidermal adipocytes than did the HFBL1 and HFBL10 groups (Figure 1 C).

Figure 1: Effect of BWE on relative omental fat weight (A), relative epididymal fat weight (B), epididymal adipocyte size (C), and relative liver weight (D) in HFD-induced obese rats. Values are expressed as mean ± SEM (n = 8 for tissue/organ weight, whereas n = 3 for adipocyte size). *p < 0.05 vs. control, †p < 0.05 vs. HF. C: control; HF: HFD alone; HFB1: HFD + BWE 41.3 mg/kg; HFB10: HFD + BWE 413 mg/kg

Effect of BWE on hepatic TG accumulation

HFDs not only induced obesity but also elevated circulating blood lipid levels. HFD-fed rats showed increased levels of TC (25.6% increase) and TG (41.8% increase) compared with the control animals. TC and LDL-C levels in the HFB1 group did not differ from the C group. However, the lipid serum profile of the HFB10 group was attenuated. This was manifested in the reduced serum TG concentrations (18.9% reduction) compared with the C group (Table 3). The HF group had a significant (p < 0.05) increase in the liver TG content. In comparison with the HF group, BWE supplementation prevented the robust increase in hepatic TG in the HFB1 and HFB10 groups (Figure 3). Moreover, BWE-fed rats had fewer visible signs of microvesicular or macrovesicular liver steatosis compared with HF rats (Figure 4). HMGCR activity increased significantly in the HF group compared with all treated groups (Figure 5).

Table 2: General characteristics of rat groups and their consumption

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Daily amount of diet (g)</th>
<th>Daily energy intake (kcal)</th>
<th>Initial body weight (g)</th>
<th>Final body weight (g)</th>
<th>Body weight gain (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>24.6 ± 0.3</td>
<td>74.8 ± 1.0</td>
<td>241.7 ± 2.8</td>
<td>367.4 ± 4.6</td>
<td>125.9 ± 3.6</td>
</tr>
<tr>
<td>HF</td>
<td>22.3 ± 0.3 *</td>
<td>113.9 ± 1.5 *</td>
<td>241.3 ± 3.5</td>
<td>414.4 ± 12.1 *</td>
<td>173.4 ± 9.0 *</td>
</tr>
<tr>
<td>HFB1</td>
<td>21.4 ± 0.2 *</td>
<td>110.0 ± 1.3 *</td>
<td>241.6 ± 3.1</td>
<td>414.1 ± 8.8 *</td>
<td>172.6 ± 7.5 *</td>
</tr>
<tr>
<td>HFB10</td>
<td>19.8 ± 0.6 *</td>
<td>101.5 ± 2.9 *</td>
<td>243.1 ± 3.4</td>
<td>399.6 ± 6.6 *</td>
<td>156.5 ± 7.9 *</td>
</tr>
</tbody>
</table>

Values are mean ± SEM (n = 8); *p < 0.05 vs. control; C: control; HF: HFD alone; HFB1: HFD + BWE 41.3 mg/kg; HFB10: HFD + BWE 413 mg/kg

Table 3: Effect of BWE on TC, LDL-C, HDL-C, and TG in serum

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Total Cholesterol (mg/dL)</th>
<th>Low-density lipoprotein-cholesterol (mg/dL)</th>
<th>High-density lipoprotein-cholesterol (mg/dL)</th>
<th>Triglycerides (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>76.2 ± 2.0</td>
<td>32.2 ± 5.3</td>
<td>38.5 ± 3.0</td>
<td>28.7 ± 1.6</td>
</tr>
<tr>
<td>HF</td>
<td>95.7 ± 2.8 *</td>
<td>40.6 ± 4.7</td>
<td>37.8 ± 4.7</td>
<td>40.7 ± 1.8 *</td>
</tr>
<tr>
<td>HFB1</td>
<td>79.4 ± 3.0 *</td>
<td>24.3 ± 2.7</td>
<td>46.9 ± 2.0 *</td>
<td>36.7 ± 2.5 *</td>
</tr>
<tr>
<td>HFB10</td>
<td>94.1 ± 4.2 *</td>
<td>41.8 ± 2.9</td>
<td>44.1 ± 2.2</td>
<td>33.0 ± 2.5 *</td>
</tr>
</tbody>
</table>

Values are mean ± SEM (n = 8); *p < 0.05 vs. control, †p < 0.05 vs. HF. C: control; HF: HFD alone; HFB1: HFD + BWE 41.3 mg/kg; HFB10: HFD + BWE 413 mg/kg
Figure 3: Hepatic lipid content. Values are mean ± SEM (n = 6); *p < 0.05 vs. control, †p < 0.05 vs. HF. TC: total cholesterol; TG: total triglycerides; C: control; HF: HFD alone; HFB1: HFD + BWE 41.3 mg/kg; HFB10: HFD + BWE 413 mg/kg

Figure 4: Histology of liver (H&E staining, 400×; scale bar = 100 μm). C: control; HF: HFD alone; HFB1: HFD + BWE 41.3 mg/kg; HFB10: HFD + BWE 413 mg/kg

Figure 5: Effect of BWE on HMGCR activities. Values are mean ± SEM (n = 3) * p < 0.05 vs. control, †p < 0.05 vs. HF. C: control; HF: HFD alone; HFB1: HFD + BWE 41.3 mg/kg; HFB10: HFD + BWE 413 mg/kg

Effect of BWE on gene expression

SREBP1 mRNA (Figure 6A) and protein (Figure 6C) levels were significantly increased in the HF group compared with the C group, resulting in hepatic accumulation. However, the HFB10 group had SREBP1 mRNA and protein levels that were significantly lower than the HF group. Thus, BWE administration reduced inflammation by down-regulating liver NF-κB mRNA levels, as observed in the HFB10 group.

Figure 6: Effect of BWE on gene expression in HFD-induced obese rat livers. mRNA levels of SREBP-1 (A) and NF-κB p65 (B). Relative protein expression levels of SREBP-1 (C) and NF-κB (D). Values are mean ± SEM (n = 6); * p < 0.05 vs. control, †p < 0.05 vs. HF. C: control; HF: HFD alone; HFB1: HFD + BWE 41.3 mg/kg; HFB10: HFD + BWE 413 mg/kg

DISCUSSION

Obesity, dyslipidemia, hypertension, impaired glucose tolerance, and insulin resistance are a cluster of metabolic syndromes. Rats fed HFDs can develop these syndromes [16]. Benjakul is recognized in the Ayurvedic system of medicine for the control of body homeostasis [9]. Furthermore, a recent study suggested that piperine, an active ingredient in BWE, significantly lowers lipid and anti-obesity activity with no change in appetite [17]. In this study, TG levels were elevated in the HF group, indicating an increase in lipid metabolism and an energetic metabolic shift from glucose to lipids. Thus, treatment with BWE at low and high doses decreased the levels of TG in serum, resulting in attenuation of lipid metabolism. Moreover, the serum LDL-C levels were also significantly lower in HFB1 rats compared with those in the HF group.

Previous lipid metabolism studies demonstrated a correlation between lowering LDL-C and the reduction of metabolic syndrome, especially in cases of cardiovascular disease. HDL-C levels are also low in hyperlipidemia animal models [18]. However, substantial changes in HDL-C levels were not observed in the current study. Here, low doses of BWE were able to neutralize lipid metabolism. Excessive caloric intake from
dietary fat causes TG storage in adipose tissue, resulting in an accumulation of visceral fat and may further cause adipocyte malfunction [19]. Importantly, reduced epididymal adipocyte size was observed in both groups that received BWE compared to the group fed a HFD alone ($p < 0.05$). Hence, improvement in metabolic rates generally correlates with a reduction in fat mass and size [20].

A hallmark of NAFLD is the accumulation of TG within hepatocytes. This arises from an imbalance between fatty acid synthesis and removal [3]. In this study, rats were fed HFDs, leading to the development of obesity, hypertriglyceridemia, and hypercholesterolemia. Rats fed HFDs and BWE showed fewer signs of microvesicular and macrovesicular liver steatosis when compared with rats fed only HFDs. These findings were associated with decreased HMGCR activity and SREBP-1 expression. De novo fatty acid synthesis was also regulated by the transcription factor SREBP1 that stimulates liver TG synthesis. The lipogenic enzymes involved these pathways, including fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) [21]. The activity of HMGCR, a hepatic enzyme, correlates closely with cholesterologenesis in target tissues and is the rate-limiting step in the synthesis of cholesterol. Defective regulation of HMGCR results in the accumulation of hepatic cholesterol in humans and rodents with metabolic syndrome [22].

Inflammation induced by hepatocyte stress responses may lead to lipid accumulation. Furthermore, dietary cholesterol is absorbed by the intestine, then entering to the hepatocyte. It is not only a lipid risk factor but also initiates the hepatic inflammation [23]. HFD-induced obesity in animal models is associated with hepatic steatosis and increased hepatic NF-κB activity [24]. Here, BWE supplementation decreased the relative mRNA and protein expression of hepatic NF-κB. These data indicate that BWE supplementation obstructs NF-κB signaling, resulting in inhibition of liver inflammation.

No signs of gross toxicity were found after four weeks of BWE treatment. There are no harmful active ingredients found in BWE, even from Plumbagin, which may contain a toxic substance [25].

CONCLUSION

BWE treatment may prevent the initial development of metabolic syndrome. However, BWE can be considered an alternative nutritional supplement in preventive strategies to prevent or reduce fat deposition and obesity-associated complications.

DECLARATIONS

Acknowledgement

This work was supported by grants from the Research Unit, Faculty of Medicine, Thammasat University, Thailand.

Conflict of interest

No conflict of interest is associated with this work.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES


